Navigation Links
Mylan Announces Pricing of Add-On Offering of Senior Notes
Date:7/30/2010

PITTSBURGH, July 30 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it priced $300 million aggregate principal amount of Senior Notes due 2020 at an issue price of 105.5% with a coupon of 7.875%, or an effective yield to maturity of 7.087%. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of 7.875% Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued 7.875% Senior Notes due 2020 will be treated as a single class of notes under the indenture.

Mylan intends to use the net proceeds of this offering to finance a portion of the $550 million purchase price for the previously-announced acquisition of all of the equity of Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company. The closing of this offering will not be conditioned on consummation of the Bioniche Pharma acquisition. If the Bioniche Pharma acquisition is not consummated, Mylan intends to use the net proceeds from the offering for general corporate purposes, which may include repayment of indebtedness or business development opportunities. Subject to customary closing conditions, the sale of the notes is expected to close on or about August 13, 2010.

The notes will be sold only to qualified institutional buyers in the U.S. in reliance on Rule 144A under the Securities Act of 1933, and outside the U.S. to non-U.S. persons in reliance on Regulation S under the Securities Act. The notes will not be registered under the Securities Act, and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to Mylan's failure to consummate the private placement or to utilize the proceeds of such placement as described in this press release. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by Mylan or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors set forth in Mylan's Quarterly Report on Form 10-Q for the period ended June 30, 2010 and in its other periodic filings made with the SEC from time to time.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
2. Mylan Announces Settlement Agreement for Namenda®
3. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
4. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
5. Mylan Receives Approval for Nabumetone Tablets
6. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
7. Mylan Receives Approval for Generic Version of Arimidex® Tablets
8. Mylan Receives Approval for Generic Version of Zocor® Tablets
9. Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
10. Mylan Receives Approval for Generic Version of Neurontin® Tablets
11. Mylan Receives Approval for Generic Version of Valtrex®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Providing broad access to ... opposition, but there is a better way to address this problem. , That was ... Pharmacy, Public Policy and Economics at the University of Southern California, who served as ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs ... has kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which ... Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” ... next project in the company’s esteemed VISION House demonstration project series. Manifesting the concept ... amount of resources they need to live affordably and abundantly without unduly taxing the ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry , an ... an active lifestyle company that provides Human Performance Training and education to tactical ... first responders, military officers and others in service through the development and conditioning ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern ... Regional Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. This ... physicians and healthcare providers an opportunity to learn about cutting edge treatments, to ...
Breaking Medicine News(10 mins):